A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer

Inclusion Criteria

• •Age ≥18 years in US
• •Histologically or cytologically documented advanced or metastatic NSCLC
• •At least one sample available and evaluable for HER3 expression
• •For Cohort 1:
• •Tissue sample collected on or after January 1, 2013
• •For Cohort 2:
• •EGFRm NSCLC previously treated with a 3rd generation EGFR TKI
• •2 samples are available and evaluable for HER3 expression at 2 timepoints: one pre-treatment and one post-treatment, where the treatment is a 3rd generation TKI (defined as Osimertinib, Aumolertinib \[formerly Almonertinib\])
• •For Cohort 3:
• •ALK+ NSCLC
• •2 samples are available and evaluable for HER3 expression at 2 timepoints: one pre-treatment and one post-treatment, where the treatment is a TKI
• •For Cohort 4:
• •NSCLC harboring a KRAS p.G12C mutation or EGFR exon 20 insertion
• •2 samples are available and evaluable for HER3 expression at 2 timepoints: one pre-treatment and one post-treatment